Elanco Animal Health Inc (ELAN)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA and an Investment Account

Sell

$20.70

Buy

$22.18

arrow-up$0.02 (+0.09%)

Prices updated at 13 Dec 2025, 00:38 EST

Prices minimum 15 mins delay

Prices in USD

S&P 500

-1.07%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Chairman

Mr. Lawrence E. Kurzius

CEO

Mr. Jeffrey N. Simmons

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

9,450

Head office

2500 Innovation Way

Greenfield

United States

46140

+1 877 352-6261

greffet_james_f@elanco.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Robert M. VanHimbergen Executive Vice President and Chief Financial Officer	-
Mr. Art A. Garcia Independent Director	0.09m
Dr. Deborah T. Kochevar, D.V.M.,PhD Independent Director	0.11m
Mr. Lawrence E. Kurzius Chairman of the Board	0.19m
Mr. R. David Hoover Independent Director	0.16m
Mr. Jeffrey N. Simmons President, Chief Executive Officer and Director	1.20m
Mr. Paul S. Herendeen Independent Director	0.09m
Mr. Michael J. Harrington Independent Director	0.10m
Dr. Denise Vera Scots-Knight, PhD Independent Director	0.09m
Ms. Kapila Kapur Anand Independent Director	0.12m
Mr. David S. Kinard Executive Vice President, Human Resources, Corporate Communications and Administration	-
Mr. Ramiro Martin Cabral Executive Vice President and President of Elanco International	0.62m
Mr. James M. Meer Senior Vice President and Chief Accounting Officer	-
Mr. Kirk McDonald Independent Director	0.10m
Mr. Timothy J. Bettington Executive Vice President, Corporate Strategy and Market Development	0.64m
Mr. Jose Manuel Correia de Simas, PhD Executive Vice President, U.S. Farm Animal Business	-
Dr. Stacey Ma, PhD Independent Director	0.01m
Ms. Ellen de Brabander, PhD Executive Vice President, Innovation and Regulatory Affairs	0.75m
Mr. Rajeev A. Modi Executive Vice President, U.S. Pet Health and Global Digital Transformation	-
Ms. Grace McArdle Executive Vice President, Manufacturing and Quality	-
Ms. Shiv O'Neill Executive Vice President, General Counsel and Corporate Secretary	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Dodge & Cox	82,759,837
FMR Inc	65,357,380
Fidelity Management and Research Company	65,357,380
Dodge & Cox Stock Fund	55,341,300
PRIMECAP Management Company	49,958,156

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2024	-
27 Dec 2024	-
27 Dec 2024	-
13 Dec 2024	-
13 Dec 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
15 Nov 2024	-
15 Nov 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.